Association of titin and myosin heavy chain in developing skeletal muscle.

Proc Natl Acad Sci U S A

Department of Biochemistry, University of Iowa, Iowa City 52242.

Published: August 1992

To understand molecular interactions that organize developing myofibrils, we examined the biosynthesis and interaction of titin and myosin heavy chain in cultures of developing muscle. Use of pulse-labeling, immunoprecipitation, and a reversible cross-linking procedure demonstrates that within minutes of synthesis, titin and myosin heavy chain can be chemically cross-linked into very large, detergent-resistant complexes retaining many features of intact myotubes. These complexes, predominantly of titin and myosin, occur very early in myofibrillogenesis as well as later. These data suggest that synthesis and assembly of titin and myosin are temporally and spatially coordinated in nascent myofibrils and support the hypothesis that titin molecules help to organize sarcomere formation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC49737PMC
http://dx.doi.org/10.1073/pnas.89.16.7496DOI Listing

Publication Analysis

Top Keywords

titin myosin
20
myosin heavy
12
heavy chain
12
myosin
5
titin
5
association titin
4
chain developing
4
developing skeletal
4
skeletal muscle
4
muscle understand
4

Similar Publications

Background: Pulmonary hypertension (PH) often leads to right ventricle (RV) failure, a significant cause of morbidity and mortality. Despite advancements in PH management, progression to RV maladaptation and subsequent failure remain a clinical challenge. This study explored the effect of paroxetine, a selective serotonin reuptake inhibitor (SSRI), on RV function in a rat model of PH, hypothesizing that it improves RV function by inhibiting G protein-coupled receptor kinase 2 (GRK2) and altering myofilament protein phosphorylation.

View Article and Find Full Text PDF

Hypertrophic cardiomyopathy: insights into pathophysiology and novel therapeutic strategies from clinical studies.

Egypt Heart J

January 2025

Department of Physiology, Faculty of Basic Medical Sciences, Obafemi Awolowo College of Health Sciences, Olabisi Onabanjo University, Sagamu Campus, Sagamu, Ogun State, Nigeria.

Background: Hypertrophic cardiomyopathy (HCM) is a frequently encountered cardiac condition worldwide, often inherited, and characterized by intricate phenotypic and genetic manifestations. The natural progression of HCM is diverse, largely due to mutations in the contractile and relaxation proteins of the heart. These mutations disrupt the normal structure and functioning of the heart muscle, particularly affecting genes that encode proteins involved in the contraction and relaxation of cardiac muscle.

View Article and Find Full Text PDF
Article Synopsis
  • Cirrhotic cardiomyopathy is characterized by both systolic and diastolic dysfunction in patients with cirrhosis, resulting from abnormalities in heart muscle cells (cardiomyocytes) without any underlying heart disease.
  • Changes at the cellular level include altered membrane fluidity and dysfunctional receptors (like beta-adrenergic), as well as issues with calcium and ion transport processes, impacting overall heart function.
  • The heart in cirrhotic patients also undergoes fibrotic changes similar to those in the liver, leading to stiffness and further dysfunction, compounded by excessive cell death of cardiomyocytes.
View Article and Find Full Text PDF

Titin is the third contractile filament in the sarcomere, and it plays a critical role in sarcomere integrity and both passive and active tension. Unlike the thick and thin filaments, which are polymers of myosin and actin, respectively, titin is a single protein that spans from Z-disk to M-line. The N2A region within titin has been identified as a signaling hub for the muscle and is shown to be involved in multiple interactions.

View Article and Find Full Text PDF

Heart failure with preserved ejection fraction (HFpEF) is a major public health challenge, affecting millions worldwide and placing a significant burden on healthcare systems due to high hospitalization rates and limited treatment options. HFpEF is characterized by impaired cardiac relaxation, or diastolic dysfunction. However, there are no therapies that directly treat the primary feature of the disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!